Valeant Pharmaceuticals VRX
Valeant is channel-stuffing through a web of captive specialty pharmacies (Philidor, R&O, plus cloned shells) to fabricate invoices and book phantom revenue — a potential Pharmaceutical Enron; price target $50.
Thesis
Citron argues Valeant has constructed a network of captive specialty pharmacies — Philidor RX, R&O, West Wilshire, SafeRx, and Orbit — to manufacture phantom sales and evade auditor scrutiny. The smoking gun: R&O and Philidor share identical patient privacy notices, the same Privacy Officer toll-free number (855-815-7688), and the shell domains were all registered on the same day. Valeant's sudden disclosure that it holds an option to acquire Philidor and already consolidates its financials — revealed only after SIRF and NYT reporting forced the issue — is framed as a coverup, not transparency. Citron draws direct parallels to Enron (McKinsey-pedigree CEO, defensive rhetoric, 'simple model' claims) and to Arthrocare/Discocare, where a similar captive-pharmacy structure ended in a 20-year prison sentence for the CEO. Price target cut to $50.
SCQA
Valeant is a hedge-fund-darling big-cap pharma that grew through serial acquisitions of Salix, Bausch & Lomb, and others, slashed R&D, and hiked drug prices aggressively under McKinsey-bred CEO J. Michael Pearson.
Philidor, a captive specialty pharmacy Valeant secretly consolidated, appears to own clone pharmacies (R&O, West Wilshire, SafeRx, Orbit) sharing phone numbers and privacy notices — evidence of fabricated invoices and channel-stuffed revenue hidden from auditors.
Investors should treat the Philidor disclosure as a coverup rather than transparency, absorb the Enron and Arthrocare precedents, and exit before regulators and auditors unwind the captive-pharmacy consolidation.
Price target cut to $50 with material further downside if the captive-pharmacy revenue is confirmed fraudulent; Arthrocare precedent points to criminal exposure for leadership.
The three reasons
- 1
Philidor and R&O Pharmacy are the same entity — phantom accounts used to book revenue
- 2
Valeant built a network of captive clone pharmacies (Orbit, West Wilshire, SafeRx) to stuff the channel
- 3
Pattern mirrors Enron: McKinsey-bred CEO, hidden consolidation, rhetoric of being misunderstood
Primary demands
- Investors should treat Valeant as a potential fraud and exit the stock
- Auditors and regulators should investigate the undisclosed Philidor relationship and captive-pharmacy network
- Board audit committee (chaired by Norma Provencio) should be held accountable for non-disclosure
KPIs cited
Pattern membership
Precedents cited
- Enron (Skilling, Lay, Fastow rhetoric and collapse)
- Arthrocare / Discocare captive-pharmacy scheme (CEO sentenced to 20 years)
- Signalife / Mitchell Stein (Norma Provencio prior association)
Composition what's on the 7 slides
Slide gallery ·
Notes
Landmark Citron short report that catalyzed Valeant's collapse. Not a slide deck — a text-heavy research note with embedded evidence screenshots (Valeant's own investor slide about R&O, matched privacy-notice PDFs proving Philidor and R&O share management, same toll-free Privacy Officer number across clone pharmacies). Core rhetorical moves: (1) 'Smoking Gun' SCQA framing anchored on identical website boilerplate, (2) side-by-side Enron/Valeant CEO quote table on p6, (3) Skilling-vs-Pearson bio parallel (both ex-McKinsey, 0 yrs operating experience), (4) Arthrocare/Discocare historical analog with 'CEO now doing 20 years' kicker. Closes with Galileo epigraph and 'Extremely Cautious Investing to All' sign-off. Villain-naming extends beyond CEO to audit committee chair, citing Bronte Capital post on Signalife/Mitchell Stein association. No individual author credited on document (signed only 'Citron Research'; Andrew Left is the known founder but not named in the PDF). No formal valuation model — just a $50 price target.